MedTrace Logo

GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer

NCT00617968 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2009-09-02

No results posted yet for this study

Summary

Primarily to evaluate the rates of clinical and radiological response in the 2 groups. Secondarily rate of histological response.

Conditions

  • Breast Neoplasms

Interventions

DRUG

DOCETAXEL

Sponsors & Collaborators

Principal Investigators

  • Nathalie BILLON · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Completion
2005-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00617968 on ClinicalTrials.gov